According to the study, using the dapivirine vaginal ring in the second and third trimesters does not pose any safety risks.

Published Date: 06 Mar 2024

No safety concerns were discovered with the use of the monthly dapivirine vaginal ring starting during the second trimester of pregnancy and up until the time of the third and final cohort of the DELIVER (MTN-042) Phase Ib study.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Breast Cancer Patients Living Longer Post-Medicaid Expansion

2.

Error on the MGUS-Autoimmune Disease Association.

3.

Patients with chronic myeloid leukemia who take nilotinib are at higher risk for diabetes and hyperlipidemia.

4.

The majority of cancer medications that receive expedited approval end up failing confirmatory trials.

5.

Unified Neuro/Psych Residency Program: New Proposal.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot